

## Moving the Dial--Improving California Maternity Outcomes Together: Examining Maternal Morbidity

Christa Sakowski, RN, MSN
Clinical Lead, CMQCC
Co-lead for the Supporting Vaginal Birth
Reducing Primary Cesarean Collaborative



### What are We Talking About Today?

- Origin Story
- The rise of maternal mortality in the state of California
- Maternal Data Center
- Severe Maternal Morbidity (SMM)
- Toolkits
- Lessons Learned
- CMQCC Resources



### **CMQCC Story**


- Our mission is to end preventable morbidity, mortality and racial disparities in California maternity care
- Initial Funding from the Dept. of Public Health
  - Rise in maternal mortality—needed study and action
  - □ Further funding has come from CDC, CDPH, CHCF, RWJ, others
- Multi-organization, multi-disciplinary



#### Maternal Mortality Rate, California and United States; 1999-2013







SOURCE: State of California, Department of Public Health, California Birth and Death Statistical Master Files, 1999-2013. Maternal mortality for California (deaths ≤ 42 days postpartum) was calculated using ICD-10 cause of death classification (codes A34, O00-O95,O98-O99). United States data and HP2020 Objective use the same codes. U.S. maternal mortality data is published by the National Center for Health Statistics (NCHS) through 2007 only. U.S. maternal mortality rates from 2008 through-2013 were calculated using CDC Wonder Online Database, accessed at <a href="http://wonder.cdc.govon">http://wonder.cdc.govon</a> March 11, 2015. Produced by California Department of Public Health, Center for Family Health, Maternal, Child and Adolescent Health Division, March, 2015.



### CMQCC's Key Stakeholders/ Partners

#### **State Agencies**

- CA Department of Public Health, MCAH
- Regional Perinatal Programs of California (RPPC)
- DHCS: Medi-Cal
- Office of Vital Records
- Office of Statewide Health Planning and Development (OSHPD)
- Covered California

#### **Membership Associations**

- California Hospital Association (CHA)
- Pacific Business Group on Health (PBGH)
- Integrated Healthcare Association (IHA)

#### **Key Medical and Nursing Leaders**

UCs, Stanford, Kaiser (N&S), Sutter, Sharp,
 Dignity Health, Scripps, Providence, Public hospitals

### Professional Groups (California sections of national organizations)

- American College of Obstetrics and Gynecology (ACOG)
- Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN)
- American College of Nurse Midwives (ACNM),
- American Academy of Family Physicians (AAFP)

#### **Public and Consumer Groups**

- Consumers' Union
- March of Dimes (MOD)
- California HealthCare Foundation (CHCF)
- Cal Hospital Compare
- Amniotic Fluid Embolism Foundation



## 1 Turning Mortality Reviews Into Action

- Multidisciplinary Review Committee focused on what were the potential improvement opportunities seen in each case
- Foundation for QI Toolkits
- Hemorrhage and hypertension are the most preventable causes of mortality and the drivers for 75% of severe maternal complications
- Maternal mortality has proven to be a great motivator for introducing changes on L&D



# Toolkits Inspired by Maternal Mortality Reviews

- Obstetric Hemorrhage
- Preeclampsia
- VTE Prevention
- Cardiovascular Disease
- Coming Soon!
  Infection / Sepsis




## 2 Low-Burden Rapid-Cycle Data

- Data collection burden is the undoing of many QI projects
- Most state data sources are 1-2 years old before they are provided back to hospitals
- Hospitals have little sense of how they compare to others
- Providers have NO sense of how they compare to others
- 213 member hospitals

#### California Maternal Data Center






Links over 1,000,000 mother/baby records each year


#### California Maternal Data Center







# Measure Analysis: Identify "Drivers" of the CS Rate



Screen Shot from the CMQCC Maternal Data Center





- Teams must involve admin, physicians and nursing at minimum
- Informal leaders often have the best results
- Critical to engage nursing for all projects
- Unit culture drives success




## 4 It is all about Variation in Practice

- Data show variation in care beyond anything explained by patient characteristics
  - Total Cesarean rate
  - NTSV Cesarean rate
  - Episiotomy rate
  - VBAC rate
  - □ 3<sup>rd</sup>/ 4<sup>th</sup> degree laceration rate
  - Induction rate
  - Severe Maternal Morbidity rate



# Variation in NTSV Cesarean Rate among 243 CA Hospitals (2015)





## 5 The Need for Balancing Measures

- Every QI project needs to have measure(s) or indicator(s) for unexpected harm (safety)
- For maternity care, often need safety metrics for both mother and baby



### **Evaluating Severe Maternal Morbidity**



### Severe Maternal Morbidity (SMM)

- Severe <u>Maternal Morbidity</u> (SMM) Unanticipated outcomes of the labor and delivery process that result in significant short or long term consequences to a woman's health<sup>1</sup>
- Conditions associated with transfer to intensive care or a higher level of care
- 19 indicators have been identified by the CDC and based on ICD-10 diagnosis codes



#### **CDC SMM Diagnosis Codes:**

- Acute myocardial infarction
- **Aneurysm**
- **Acute renal failure**
- Adult respiratory distress syndrome (ARDS)
- Amniotic fluid embolism
- Cardiac arrest/ventricular fibrillation
- **Conversion of cardiac rhythm**
- Disseminated intravascular coagulation
- **Eclampsia**
- Heart failure/arrest during surgery or procedure
- Puerperal cerebrovascular disorders



#### CDC SMM Diagnosis Codes (cont.)

- Puerperal cerebrovascular disorders
- Pulmonary edema/acute heart failure
- Severe anesthesia complications
- **Sepsis**
- Shock
- Sickle cell disease with crisis
- Air and thrombotic embolism
- **Blood transfusion**
- Hysterectomy
- **Temporary tracheostomy**

**Ventilation** 

CDC-


https://www.cdc.gov/repr oductivehealth/maternali nfanthealth/smm/severe -morbidity-ICD.htm

Last updated 2/7/18



### Why Focus on SMM?






CDC, Updated 11/27/17



#### **MDC SMM Without Transfusions**





### Importance of SMM

- Can be considered "near misses"
- If cases are not identified and treated, they have the possibility of escalating to maternal death
- Reviewing incidents of SMM provides a unique opportunity to improve our understanding of the primary contributing factors of these conditions with a potential to improve the health care delivery system<sup>4</sup>



# SMM Case Debriefings for Improvement and Sustainability

- Review your hospital data (MDC)
- Track and trend the data routinely frequency based on delivery volume
- Perform a case review on all fallouts to determine opportunities for improvement



#### **Case Review Process**

- Does the case qualify?
- Participants in the review process should include members of the health care team involved in the care of the patient



#### **Case Review Process (cont.)**

- Review prenatal record to identify risk factors
- Was patient informed of risk? Shared Decision Making
- Comprehensive H&P completed and documented on admission?
- Appropriate personnel/preparation available as indicated by H&P review/hospital policy?
- Communication handoffs between caregivers regarding patient Hx, condition changes & delivery summary completed?



#### **Case Review Process (cont.)**

- Patient condition monitored at the correct frequency?
- Patient/family kept informed of the condition with documentation to support
- Neonatal team kept informed of the patient condition on admission and throughout the labor process?
- Opportunities for improvement?



#### **Action Steps for Improvement and Sustainability**

- Set the expectation for quality sustainability
- Systematic review of bundle compliance for all toolkits at least quarterly. (MDC assists with data review prompts and cases available for review)
  - Review SMM trends as an outcome measure for all interventions and sustainability activities
  - Report quality findings to the OB health care team, Quality Department and Administration



# Action Steps for Improvement and Sustainability (cont.)

- Establish action plans for any identified opportunities for improvement
- Set stretch (bold) goals
- Small tests of change to evaluate action plans
  - □ Start with "early wins" and advance to bigger projects as goals are achieved
- Celebrate Successes!



# Considerations for Antepartum Approaches for Reducing SMM

- Preconception Planning education for patients focusing on pre-pregnancy control of weight, hypertension, blood sugar management, activity
- Childbirth education to set the expectation for the labor process and reduce the likelihood of primary cesareans
- Open a dialogue regarding alternative birthing options at your facility (VBAC's, midwives, doulas, delayed admissions, intermittent fetal monitoring, etc.)



#### **Communication and Preparation**

- The most frequent identified drivers of SMM are transfusions and sepsis
- SMM reduction strategy suggestions focus on communication and preparation
  - □ Insist on complete prenatal records which focus on risk factors.
    Add risk factors to hospital problem list.
  - □ Complete nursing care plans on identified risk factors with preparation plan documented
  - Ensure comprehensive assessments for identified risk factors are completed on admission (hemorrhage risk assessments, lab work analysis, GBS status)



#### **Communication and Preparation**

- Ensure systematic and ongoing assessments are completed and documented throughout the labor, delivery and postpartum process
  - Blood loss, time elapsed since rupture of membranes, vital signs including maternal temperature, fetal heart rate
- Have all required personnel and equipment available on the unit/at the bedside when risk factors are identified
  - □ Anesthesia, Scrub tech, blood products ordered, hemorrhage cart



#### **Summary**

- Monitor quality outcomes
- Consider monitoring outcomes using different filters (MDC)
  - By race, NICU level, payer
  - □ Are you meeting your goals for all of your patients
- Review your SMM measure analysis outcomes to identify trends (MDC)
- Involve your team members in the quality improvement plans to ensure sustainability



## **CMQCC** Toolkits



#### **CMQCC Maternal Quality Improvement Toolkits**

- Aim to improve the health care response to leading causes of preventable death among pregnant and postpartum women
- Include a compendium of best practice tools and articles, care guidelines in multiple formats, hospital-level implementation guide, and professional education slide set.
- Developed in partnership with key experts from across California, representing the diverse professionals and institutions that care for pregnant and postpartum women.



#### **CMQCC** Toolkits

- Elimination of Non-medically Indicated (Elective) Deliveries Before 39 Weeks Gestational Age
- Improving Health Care Response to Preeclampsia
- Improving Health Care Response to Obstetric Hemorrhage
- Support Vaginal Birth and Reduce Primary Cesareans,
- Improving Health Care Response to Cardiovascular Disease in Pregnancy and Postpartum
- Improving Health Care Response to Maternal Venous Thromboembolism
- Coming Soon! Maternal Sepsis






# or More Information and to Download the Toolkits

- Visit our website:
  - www.cmqcc.org
- Or contact us:
  - info@cmqcc.org



# CA-PAMR Findings Timing of Diagnosis and Death 2002-2006

Timing of CVD Diagnosis (n=64)



#### Timing of Death

- 30% of all CVD deaths were >42 days from birth/fetal demise vs.
   7.3% of non CVD pregnancy-related deaths
- Driven by Cardiomyopathy deaths, with 42.9% deaths >42 days

Hameed A, Lawton E, McCain CL, et al. Pregnancy-Related Cardiovascular Deaths in California: Beyond Peripartum Cardiomyopathy. *American Journal of Obstetrics and Gynecology* 2015; DOI: 10.1016/j.ajog.2015.05.008



#### Rationale for Toolkit

#### Cardiovascular Disease is

- the leading cause of maternal mortality in CA and U.S.
- under-recognized in pregnant or postpartum women
- higher among African-American women
- 25% of deaths attributed to cardiovascular disease may have been prevented if the woman's heart disease had been diagnosed earlier.
- Pregnancy is a period of frequent interaction with health care providers and offers an opportunity to detect and treat heart disease, improve pregnancy outcomes, and affect future cardiovascular health.



## VTE Risk Assessment: Standard Practice for all Medical Surgical Patients

- AHRQ (The Agency for Healthcare Research and Quality) defined VTE as the "number one patient safety practice" for hospitalized patients
- Joint Commission All hospitalized patients to have VTE prophylaxis or documentation why no VTE prophylaxis was given — Quality measure VTE 1
- NQF (National Quality Forum) Safe practices published recommendations:
  - luleq Routine evaluation of hospitalized patients for risk of VTE
  - Use of appropriate prophylaxis

Shojania KG, (Eds.).(2001). "Making healthcare safer; A critical analysis of patient safety practices (Evidence Report/Technology Assessment No. 43)." (AHRQ Publication NO.01-E058).

Joint Commission (2015). Specifications Manual for National Hospital Inpatient Quality Measures v.5.1

National Quality Forum. National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism. (2006)



#### **CVD Toolkit Goals**

- Encourage obstetric and other healthcare providers to retain a high index of suspicion for CVD, particularly among women with risk factors who present with symptoms in late pregnancy or early postpartum period
- To serve as resource for generalists who provide maternity care to women, with special emphasis on
  - Prenatal visits
  - Postpartum encounters
  - Emergency room visits




### **CVD** Algorithm Validation

- We applied the algorithm to 64 CVD deaths from 2002-2006 CA-PAMR.
- 56 out of 64 (88%) cases of maternal mortality would have been identified.
- Detection increased to 93% when comparison was restricted to 60 cases that were symptomatic.



#### Rationale and Resources are Divided

- Readiness
- Recognition
- Response
- Reporting / Systems Learning





#### **Risk Assessment (Readiness)**

- VTE risk assessment tools should be applied to every patient to determine risk for VTE
- Risk assessment based on major guidelines:
  - NPMS National Partnership for Maternal Safety
  - ACOG American College of Obstetricians and Gynecology
  - ACCP American College of Chest Physicians
  - RCOG Royal College Obstetricians and Gynecologists
- Pharmacologic prophylaxis may be with:
  - **■Unfractionated heparin (UFH) or**
  - Low-molecular weight heparin (LMWH)
    - LMWH is a preferred antepartum medication



## CVD Assessment Algorithm For Pregnant and Postpartum Women (Recognition)

#### **Red Flags**


- Shortness of breath at rest
- Severe orthopnea ≥ 4 pillows
- Resting HR ≥120 bpm
- Resting systolic BP ≥160 mm Hg
- Resting RR ≥30
- Oxygen saturations ≤94% with or without personal history of CVD

**PROMPT EVALUATION** and/or

hospitalization for acute symptoms

plus

CONSULTATIONS with MFM and Primary Care/Cardiology



#### CARDIOVASCULAR DISEASE ASSESSMENT IN PREGNANT and POSTPARTUM WOMEN SYMPTOMS (No Red Flags and/or no personal history of CVD, and hemodynamically stable) \*NYHA class > II VITAL SIGNS **RISK FACTORS** \*\*PHYSICAL EXAM Suggestive of Heart Failure: ABNORMAL FINDINGS Age ≥40 years Resting HR ≥110 bpm Dyspnea Heart: Loud murmur or Mild orthopnea African American Systolic BP ≥140 mm Hg Tachypnea Lung: Basilar crackles Pre-pregnancy obesity RR ≥24 Asthma unresponsive (BMI ≥35) Oxygen sat ≤96% to therapy Suggestive of Arrhythmia: Pre-existing diabetes Palpitations Hypertension Dizziness/syncope Substance use (nicotine. YES NO Suggestive of Coronary cocaine, alcohol, Artery Disease: methamphetamines) Chest pain History of chemotherapy Dyspnea Consultation indicated: ≥ 1 Symptom + ≥ 1 Vital Signs Abnormal + ≥ 1 Risk Factor or MFM and Primary **ANY COMBINATION ADDING TO ≥ 4** Care/Cardiology Obtain: EKG and BNP Echocardiogram +/- CXR if HF or valve disease is suspected, or if the BNP levels are elevated 24 hour Holter monitor, if arrhythmia suspected Referral to cardiologist for possible treadmill echo vs. CTA vs. alternative testing if postpartum Consider: CXR, CBC, Comprehensive metabolic profile, Arterial blood gas, Drug screen, TSH, etc. Follow-up within one week Results abnormal CVD highly suspected Results negative @California Department of Public Health, 2016; supported by Title V funds. Developed in partnership Signs and symptoms resolved with California Maternal Quality Care Collaborative Cardiovascular Disease in Pregnancy and

Postpartum Taskforce. Visit: www.CMQCC.org for details

Reassurance and routine follow-up



### Hemorrhage Guidelines: Staged Responses (Response)

Pre-Admission: All patients-Assess Risk

**Stage 0**: All birth- Routine Measures

Stage 1: QBL > 500 mL vag or 1000 mL CS or VS unstable with continued bleeding

Stage 2: QBL 1000-1500 mL with continued bleeding

Stage 3: QBL exceeds 1500 mL




#### **CMQCC**

Obstetric Hemorrhage Emergency Management Plan: Table Chart Format

	version 2.0	T		
	Assessments	Meds/Procedures	Blood Bank	
Stage 0 Every woman in labor/giving birth				
Stage 0 focuses on risk assessment and active management of the third stage.	Assess every woman for risk factors for hemorrhage     Measure cumulative quantitative blood loss on every birth	Active Management 3rd Stage: Oxytocin IV infusion or 10u IM Fundal Massage- vigorous, 15 seconds min.	If Medium Risk: T & Scr     If High Risk: T&C 2 U     If Positive Antibody     Screen (prenatal or current, exclude low level anti-D from     RhoGam):T&C 2 U	
Stage 1	Blood loss: > 500ml vaginal <u>or</u> >1000 ml Cesarean, <u>or</u> VS changes (by >15% <u>or</u> HR <sup>3</sup> 110, BP £85/45, O2 sat <95%)			
Stage 1 is short: activate hemorrhage protocol, initiate preparations and give Methergine IM.	Activate OB     Hemorrhage Protocol     and Checklist     Notify Charge nurse,     OB/CNM, Anesthesia     VS, O2 Sat q5'     Record cumulative     blood loss q5-15'     Weigh bloody materials     Careful inspection with     qood exposure of     vaginal walls, cervix,     uterine cavity, placenta	IV Access: at least 18gauge     Increase IV fluid (LR) and     Oxytocin rate, and repeat     fundal massage     Methergine 0.2mg IM (if     not hypertensive)     May repeat if good     response to first dose, BUT     otherwise move on to 2 <sup>nd</sup> level uterotonic drug (see     below)     Empty bladder: straight cath     or place foley with urimeter	- T&C 2 Units PRBCs (if not already done)	
Stage 2	Continued bleeding with total blood loss under 1500ml			
Stage 2 is focused on sequentially advancing through medications and procedures, mobilizing help and Blood Bank support, and keeping ahead with volume and blood products.	OB back to bedside (if not already there)  Extra help: 2 <sup>nd</sup> OB, Rapid Response Team (per hospital), assign roles  VS & cumulative blood loss q 5-10 min  Weigh bloody materials  Complete evaluation of vaginal wall, cervix, placenta, uterine cavity  Send additional labs, including DIC panel  If in Postpartum: Move to L&D/OR  Evaluate for special cases:  -Uterine Inversion  -Amn. Fluid Embolism	2 <sup>nd</sup> Level Uterotonic Drugs: Hemabate 250 mcg IM gr Misoprost01800 mcg SL 2 <sup>nd</sup> IV Access (at least 18gauge) Bimanual massage Vaginal Birth: (typical order) Move to OR Repair any tears D&C: r/o retained placenta Place intrauterine balloon Selective Embolization (Interventional Radiology) Cesarean Birth: (still intra-op) (typical order) Inspect broad lig, posterior uterus and retained placenta B-Lynch Suture Place intrauterine balloon	Notify Blood Bank of OB Hemorrhage Bring 2 Units PRBCs to bedside, transfuse per clinical signs – do not wait for lab values Use blood warmer for transfusion Consider thawing 2 FFP (takes 35+min), use if transfusing > 2u PRBCs Determine availability of additional RBCs and other Coag products	
Stage 3	Total blood loss over 1500ml, <u>or</u> >2 units PRBCs given <u>or</u> VS unstable <u>or</u> suspicion of DIC			
Stage 3 is focused on the Massive Transfusion protocol and invasive surgical approaches for	Mobilize team     Advanced GYN     surgeon     2nd Anesthesia Provider     OR staff     Adult Intensivist     Repeat labs including coags and ABG's	Activate Massive Hemorrhage Protocol     Laparotomy:     B-Lynch Suture -Uterine Artery Ligation -Hysterectomy     Patient support -Fluid warmer	Transfuse Aggressively Massive Hemorrhage Pack Near 1:1 PRBC:FFP 1 PLT apheresis pack per 4-6 units PRBCs Unresponsive Coagulopathy: After 8-10 units PRBCs	
control of bleeding.	Central line     Social Worker/ family support     Public Health, 2014; supported by Title V func	-Upper body warming device -Sequential compression stockings  b. Developed in partnership with California Maternal 6	and full coagulation factor replacement: may consult re rFactor VIIa risk/benefit	

## **CMQCC OB Hemorrhage Emergency Management Plan**




is project was supported by funds received from the State of California Department of Public Health, Center for Family Health, Maternal, Child and Adolescent Health Division

Every hospital will need to customize the protocol—but the point is every hospital needs one



#### Algorithm 1: 1st Prenatal Visit Maternal VTE Risk Assessment



©California Department of Public Health, 2017; supported by Title V funds. Developed in partnership with California Maternal Quality Care Collaborative Maternal Venous Thromboembolism Task Force. Visit: <a href="https://www.CMQCC.org">www.CMQCC.org</a> for details



#### **Antepartum Outpatient Prophylaxis First Prenatal Visit**

Clinical History	Risk Level	Management
<ul> <li>Low risk thrombophilia (isolated)</li> <li>Low risk thrombophilia with family history of VTE</li> <li>Prior provoked VTE</li> </ul>	LOW	No treatment
<ul> <li>Prior VTE idiopathic</li> <li>Prior VTE with pregnancy or oral contraceptive</li> <li>Prior VTE with low risk thrombophilia</li> <li>Family history of VTE with high risk thrombophilia</li> <li>High risk or antiphospholipid syndrome (APS)</li> </ul>	MEDIUM	Prophylactic dose  LMWH or UFH
<ul> <li>Current VTE or other conditions requiring therapeutic dose of anticoagulation</li> <li>Multiple prior VTE episodes</li> <li>Prior VTE with high-risk thrombophilia</li> <li>Prior VTE with APS</li> </ul>	HIGH	Therapeutic dose  LMWH or UFH  Recommend co- management with maternal-fetal medicine and/or hematology specialist

©California Department of Public Health, 2017; supported by Title V funds. Developed in partnership with California Maternal Quality Care Collaborative Maternal Venous Thromboembolism Task Force. Visit: <a href="https://www.CMQCC.org">www.CMQCC.org</a> for details



## Racial Disparities in CVD Clinical Implications

- Listen to women. Take patient complaints seriously, and maintain a high index of suspicion for CVD especially in ALL African-American women.
- Any co-morbidity should further heighten the clinical index of suspicion.
- African-American women with chronic or gestational hypertension, high BMI (>35) who present with symptoms suggestive of CVD or vital signs indicated in the CVD Assessment Algorithm should be evaluated carefully and thoroughly for potential CVD.



### **Implementation**



#### **Lessons from the Field**

- It takes a broad team
- Easy wins matter
- Goals and timelines are very useful
- It takes time and persistence to get the systems running smoothly
- Must have champions

Disciplines & Departments	Needed?
Obstetrics	
Nursing	
Anesthesia	
Blood Bank	
Laboratory	
Operating Room	
Support personnel	
IT/EMR	
QI	
Others unique to your setting?	




#### **Team Build**





### KEY RESOURCES:



- 1) AIM Bundles
- 2) Committee Opinions
- 3) Consensus Statements
- 4) Rate transparency (unit/provider)
- 5) CMQCC Toolkits
- 6) SHARE
- 7) Education
- 8) Patient engagement
- 9) Unit culture/teamwork




#### **Share Unblinded Data**



Guidance for Understanding and Unblinding Provider-Level NTSV Cesarean Rates

#### At Start of Project

The Readiness Assessment, Structure Measures Checklist (both are found in the Implement and Chart Audit Tool are all located on the collaborative resources page at https://www.cmqcc.org/projects/toolkit-and-collaborative-support-vaginal-birth-and-reducesareans/collaborative



HP2020 Target: ≤23.9%

**16.7%** (2/12) **17.2%** (5/29)

17.6% (3/17)

29.7% (102/343)

33.3% (4/12)

38% 41/108

40% (4/10)

**6.3%** (1/16) **7.1%** (1/14)


10.7% (3/28)



### **Transparency**



- Every Year the CA Secretary of HHS Recognizes Hospitals
   With NTSV CS Rates <23.9%</li>
- CalHospitalCompare.org
- Yelp
- Joint Commission





#### PHYSICIAN BADGE TAG

#### **Physician Badge Tag**

#### Prevent Her 1st Cesarean Section

Latent Phase Arrest (Failed Induction of Labor)

- If <6cm dilated → 12 hrs of oxytocin after ROM?</li>
   Active Phase Arrest (Arrest of Dilation)
- If 6-10cm dilated + ROM → 4h with adequate uterine activity or at least 6h with inadequate uterine activity with oxytocin

#### Arrest of Descent (2<sup>nd</sup> stage)

 If completely dilated → pushing ≥3hr without epidural in Second Stage (or 4hrs with epidural)

#### **Elective Induction of Labor**

- · Prior to 41 weeks
- Bishop score ≥ 8 (nulliparous); ≥6 (multiparous)
   Physician Documentation (tell the story)
- Labor management
- Decision/rationale for C-section


<u>Laborist Contact Number</u> #(818)885-8500 ext. 5350


## Education and Adoption of Guidelines















#### **Celebrate Success!!!**














## On-Line Short Modules for Teaching Labor Support







## CMQCC QI Academy

- Goal: facilitate the development of OB quality improvement leaders on every OB unit
- Apply QI concepts and techniques to your project
- Year long program
- Hospital multi-disciplinary teams
- National and CA faculty
- New cohort every 6 months
- CEU/MOC credit for participation in the program



## Sometimes it doesn't quite turn out the way you planned!







### **Strategies**

- Regroup with your team
- Elicit a broader range of support
- Review your data
- Reach out to CMQCC





